Integrated Services Core
Integrated Services Core
批准号:
10793945
负责人:
William Paul Duprex
金额:
$115.86万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-18 至 2028-07-31
关键词:
AccelerationAdministratorAerosolsAlphavirusAnimal ModelAnimalsAvian Influenza A VirusBiologicalBiologyBioluminescenceBioterrorismCellsCellular biologyClinicalComplexConfocal MicroscopyCoronavirusCreativenessDataDimensionsDisciplineDisease modelEmergency SituationEmerging Communicable DiseasesEngineeringEnsureEquipmentEventEvolutionFelis catusFerretsFluorescenceHamstersImmune responseImmunoassayImmunology procedureIn VitroInfectionInfrastructureInternationalInterventionInvestmentsLaboratoriesLaboratory PersonnelLaboratory ResearchLaboratory TechniciansMissionModelingMonitorMusOrthobunyavirusOrthomyxoviridaeOryctolagus cuniculusPET/CT scanPathogenesisPathogenicityRattusRecombinantsReporter GenesReportingResearchResearch InfrastructureResearch PersonnelRestRodentRunningScientistSecureServicesSideSystemTestingTherapeuticTherapeutic InterventionTissuesToxinTrainingUniversitiesVaccine ResearchVeterinariansViralVisionWorkarmbiodefensebioimagingbiosafety level 3 facilitybiosecuritycohortdigitalemerging pathogenexperienceimaging capabilitiesin vivoin vivo imagingmedical countermeasuremultimodalitynonhuman primatenoveloperationpandemic diseasepandemic preparednesspathogenpreclinical developmentprogramsprophylacticquality assuranceresearch facilityresponsereverse geneticssingle cell sequencingsingle moleculesingle photon emission computed tomographytransmission processwhole body imaging
中文摘要
集成服务核心
摘要:
该大学疫苗研究中心(CVR)内的区域生物防护实验室(RBL)
匹兹堡大学是生物安全3级(BSL-3)感染生物学中心。RBL的使命有三个方面,
致力于病原体的出现、进化和宿主间传播,研究
新出现的传染病,并加快新的干预措施和医疗
预防大流行和生物防御的对策。我们的愿景是成为一个全球公认的,高度-
协作,创造性和前瞻性的感染生物学家团队谁是准备应对新出现的
在国家和国际一级的生物威胁。整个设施都已在
选择代理和毒素(DSAT)。它汇集了来自不同学科的感染生物学家和临床医生
他们需要BSL-3和动物(A)BSL-3设施进行广泛的病毒和细菌研究计划。
生物防护工作操作复杂,基础设施密集,监管全面。运行
BSL-3实验室的安全,可靠和成功的要求有一个组织良好,高度集成
管理人员、科学家、生物安全/生物安保专业人员、工程师/设施工作人员和
兽医/动物技术人员。这对于多病原体、多用户研究设施尤其重要,
研究BSL-3病原体标准和筛选。综合服务核心将提供广泛的
为内部用户和外部合作者提供高质量的BSL-3和ABSL-3服务。这些将严格
由学术和服务领导监督,并在外部RBL的协助下每年进行审查
主任、其他BSL-3专家和一个内部科学咨询小组。对成果预算制的业务支助,
匹兹堡将确保我们准备好支持任何国家应对一系列新出现的传染病
如果发生另一场流行病或生物恐怖袭击。支持这群BSL-3科学家,他们可以
在紧急情况下研究新的病原体,肯定会有回报。
英文摘要
INTEGRATED SERVICES CORE
ABSTRACT:
The Regional Biocontainment Laboratory (RBL) within the Center for Vaccine Research (CVR) at the University
of Pittsburgh is the biosafety level-3 (BSL-3) hub for infection biology. The mission of the RBL is threefold, to
work on pathogen emergence, evolution and host-to-host transmission, to study the pathogenesis of
emerging infectious diseases and to accelerate pre-clinical development of novel interventions and medical
countermeasures for pandemic preparedness and biodefense. Our vision is to be a globally recognized, highly-
collaborative, creative and forward-facing team of infection biologists who are poised to respond to emerging
biological threats both at the national and international level. The entire facility is registered with the Division of
Select Agents and Toxins (DSAT). It brings together infection biologists and clinicians from a variety of disciplines
who require BSL-3 and animal (A)BSL-3 facilities for their wide ranging viral and bacterial research programs.
Biocontainment work is operationally complex, infrastructure-dense, and comprehensively regulated. Running
BSL-3 laboratories safely, securely and successfully demands having a well-organized and highly integrated
team of administrators, scientists, biosafety/biosecurity professionals, engineers/facilities staff and
veterinarians/zootechnical staff. This is especially important in multi-pathogen, multi-user research facilities that
study standard and select agent BSL-3 pathogens. The Integrated Services Core will deliver a wide range of
high quality BSL-3 and ABSL-3 services for internal users and external collaborators. These will be rigorously
overseen by Academic and Service Leads and reviewed annually with the assistance of an external RBL
Director, other BSL-3 experts and an internal Scientific Advisory Group. Operational support for the RBL in
Pittsburgh will ensure we are ready to support any national response to a range of emerging infectious diseases
in the event of another pandemic or bioterrorism attack. Supporting this cohort of BSL-3 scientists, who can pivot
to work on new pathogens in an emergency, is certain to pay dividends.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Operations Core
-
批准号:10793943
-
项目类别:
-
资助金额:$98.46万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Pitt RBL
-
批准号:10793942
-
项目类别:
-
资助金额:$287.02万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Practices Core
-
批准号:10793944
-
项目类别:
-
资助金额:$72.71万
-
财政年份:2023
-
负责人:William Paul Duprex
-
依托单位:
Administrative Supplement for Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
-
批准号:10631339
-
项目类别:
-
资助金额:$332.97万
-
财政年份:2022
-
负责人:William Paul Duprex
-
依托单位:
Development of multivalent, ultrapotent nanobody cocktails for SARS-CoV-2 neutralization
-
批准号:10444442
-
项目类别:
-
资助金额:$76.9万
-
财政年份:2022
-
负责人:William Paul Duprex
-
依托单位:
Upgrading the University of Pittsburgh Regional Biocontainment Laboratory within The Center for Vaccine Research
-
批准号:10394474
-
项目类别:
-
资助金额:$333.0万
-
财政年份:2021
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8664340
-
项目类别:
-
资助金额:$40.42万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8504483
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:9064740
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:8852530
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Shifting a Paradigm in Vaccine Safety: From Empirical to Rational Attenuation
-
批准号:9278078
-
项目类别:
-
资助金额:$40.93万
-
财政年份:2013
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8307628
-
项目类别:
-
资助金额:$7.09万
-
财政年份:2011
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8461424
-
项目类别:
-
资助金额:$10.78万
-
财政年份:2006
-
负责人:William Paul Duprex
-
依托单位:
Cell and Tissue Imaging Core
-
批准号:8709528
-
项目类别:
-
资助金额:$2.92万
-
财政年份:--
-
负责人:William Paul Duprex
-
依托单位:
海外基金